A clean sweep for Birmingham in MATRIX lung trial
Birmingham-based researchers and clinicians will play a leading role in a key national clinical trial for lung cancer patients.
The trial, termed MATRIX, aims to target novel treatments to specific patient groups, based on the genetic profile of their tumour. This genetic “stratification” approach, is phase 2 of the CRUK Stratified Medicine Programme.
In a recent national competition to determine where the study would be based, Birmingham based researchers were awarded lead status for the trial, and will also play leading roles in organising the clinical trials, and in assessing the results.
To read Chief Investigator Professor Gary Middleton’s CIIC Clinical Feature about the Matrix trial, click here.